David Roblin

David Roblin is a distinguished scientist, physician, drug developer, and life-sciences executive. He has been involved in Relation since its founding, while engaged as CEO of Juvenescence Therapeutics, an early investor in Relation. Before joining Relation, he enjoyed a career in biotech, pharma and academia developing many important medicines in research, development, and commercial roles. Major roles include COO and Chair of Scientific Translation at the Francis Crick Institute and Head of European R&D for Pfizer. He is currently also a Non-Executive Director of Nxera Pharma (TSE:4565), Non-Executive Chair of Centauri Therapeutics and remains Chair of Scientific Translation at the Crick.